Silence Therapeutics
SLN
3 hedge funds and large institutions have $10.2M invested in Silence Therapeutics in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
26% more capital invested
Capital invested by funds: $8.13M → $10.2M (+$2.08M)
0% less ownership
Funds ownership: 0.65% → 0.65% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.67K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LOAMU
1
Lombard Odier Asset Management (USA)
New York
| $10.2M | – | – | – |
|
2
Morgan Stanley
New York
| $44K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $2K | +$1.67K | +93 | New |
|
SLN Hedge Fund Activity: Q4 2020 in Review
3 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q4 2020, worth a combined $10.2M — up 26% from $8.13M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SLN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $1.67K.
- 3 institutional investors held Silence Therapeutics (SLN) as of Q4 2020, up from 2 in Q3 2020.
- Funds reported $10.2M of Silence Therapeutics stock for Q4 2020, up 26% quarter-over-quarter.
- 1 fund opened new Silence Therapeutics positions in Q4 2020 and 0 closed out, a net change of +1 holder.
- The largest Silence Therapeutics buyer in Q4 2020 was UBS Group, an estimated $1.67K added.
Based on aggregated 13F filings for Q4 2020.